Ying Li,Xiao Juan Yang,Zhan Zhan Zhang,Xiao Ning Kang,Shang Long Liu. Accuracy of preoperative serum CA19-9 levels in predicting the resectability of patients with pancreatic adenocarcinoma. Oncol Transl Med, 2018, 4: 6-9.
Accuracy of preoperative serum CA19-9 levels in predicting the resectability of patients with pancreatic adenocarcinoma
Received:January 04, 2018  Revised:March 23, 2018
View Full Text  View/Add Comment  Download reader
KeyWord:pancreatic adenocarcinoma; CA19-9; resectability
Author NameAffiliationE-mail
Ying Li Affiliated Hospital of Medical College,Qingdao University, 16 Jiangsu Road, Qingdao 266003, P. R. China ly2016qyfy@163.com 
Xiao Juan Yang Affiliated Hospital of Medical College,Qingdao University, Jiangsu Road
P R China 
 
Zhan Zhan Zhang Department of Nephropathy,Tengzhou Hospital of Traditional Chinese Medicine,Shandong Provence  
Xiao Ning Kang Affiliated Hospital of Medical College,Qingdao University, 16 Jiangsu Road, Qingdao 266003, P. R. China  
Shang Long Liu Department of General Surgery, Affiliated Hospital of Medical College,Qingdao University, 16 Jiangsu Road, Qingdao 266003, P. R. China liushanglong-1@163.com 
Hits: 406
Download times: 706
Abstract:
      Objective To assess the accuracy of preoperative serum CA19-9 levels in predicting the resectability of pancreatic adenocarcinoma. Methods Patients with biopsy-proven pancreatic adenocarcinoma who had preoperative serum CA19-9 level data were enrolled in the present retrospective analysis. Receiver operating characteristics (ROC) curve analysis was used to determine the optimal cut-off value of CA19-9. The sensitivity, specificity, positive predictive value, and negative predictive value were calculated at this cut-off point. Results Seventy-six patients with pancreatic adenocarcinoma that was considered potentially resectable according to radiological imaging were included. Of all 76 patients, 44 received complete resection of the pancreatic adenocarcinoma. The preoperative serum CA19-9 level was significantly higher in the unresectable tumor group than in the resectable tumor group (P = 0.0036). The area under the ROC curve was 0.749 (95% confidence interval [CI]: 0.637–0.842). When the cut-off value of CA19-9 was set to 359.1 U/mL, the sensitivity, specificity, positive and negative predictive values were 71.9% (95% CI: 53.3%–86.3%), 70.5% (95% CI: 54.8%–83.2%), 63.9% (95% CI: 46.0%–79.4%), and 77.5% (95% CI: 61.5%–89.2%), respectively. Conclusion The preoperative serum CA19-9 level is useful for predicting the resectability of pancreatic adenocarcinoma.
Close